Clinical trialNCT03752138WithdrawnPhase 1Interventional

TK216 and Decitabine in Treating Patients With Relapsed and Refractory Acute Myeloid Leukemia

SponsorM.D. Anderson Cancer CenterEnrollment0Recurrent Acute Myeloid LeukemiaRefractory Acute Myeloid Leukemia

View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Tapan Kadia
M.D. Anderson Cancer Center
Principal InvestigatorKOL profile →
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

No facility list is in our current data snapshot for this study. The registry record on ClinicalTrials.gov ↗ carries any published locations. Why? →

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Expansion Phase DecitabineExpansion Phase TK216Group 1: TK216Group 2: TK216Part 2: DecitabinePart 2: TK216

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 31 Mar 2019
Primary completion: 31 Dec 2020
Completion: 31 Dec 2020
Last update posted: 6 May 2019
Registered enrollment: 0
Registry id: NCT03752138

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.